A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Cautionary Note Regarding Forward-Looking Statements (Safe Harbor Statement): This Annual Report on Form 10-K (Annual Report) contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts and will often include words such as “expects”, “may”, “anticipates”, “aims”, “intends”, “would”, “could”, “should”, “will”, “plans”, “believes”, “estimates”, “targets”, “projects”, “forecasts”, “seeks” and similar words and expressions.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 28M | 26M | 17M | 19M | 19M | 15M |
| Net Income | 2.3M | -2.2M | -5.8M | -2.5M | -78K | -1.0M |
| EPS | $0.28 | $-0.26 | $-0.75 | $-0.32 | $-0.01 | $-0.14 |
| Free Cash Flow | 715K | -108K | -6.6M | -5.5M | -1.7M | -2.8M |
| ROIC | 7.0% | -6.0% | -16.3% | -6.3% | 1.1% | -2.8% |
| Gross Margin | 40.9% | 30.0% | 22.1% | 41.2% | 45.0% | 44.7% |
| Debt/Equity | 0.37 | 0.60 | 1.09 | 0.45 | 0.32 | 0.38 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 2.3M | -1.6M | -5.7M | -2.3M | 257K | -1.4M |
| Operating Margin | 8.4% | -6.2% | -32.9% | -12.4% | 1.3% | -9.0% |
| ROE | 7.8% | -8.2% | -23.1% | -8.2% | -0.2% | -3.6% |
| Shares Outstanding | 9M | 8M | 8M | 8M | 8M | 7M |
IMMUCELL CORP /DE/ passes 1 of 9 quality checks, indicating weak fundamentals.
IMMUCELL CORP /DE/ trades at 27.6x trailing earnings, compared to its 15-year median P/E of 15.0x, suggesting it is currently Expensive relative to its historical range. The company's 5-year average gross margin is 36.6%.
IMMUCELL CORP /DE/ (ICCC) has a current P/E ratio of 27.6, compared to its historical median P/E of 15.0. The stock is currently considered Expensive based on its historical valuation range.
IMMUCELL CORP /DE/ (ICCC) has a 5-year average return on invested capital (ROIC) of -6.0%. This is below average and may indicate limited pricing power.
IMMUCELL CORP /DE/ (ICCC) has a market capitalization of $70M. It is classified as a small-cap stock.
IMMUCELL CORP /DE/ (ICCC) does not currently pay a regular dividend.
Based on historical P/E analysis, IMMUCELL CORP /DE/ (ICCC) appears expensive. The current P/E of 27.6 is 84% above its historical median of 15.0.
IMMUCELL CORP /DE/ (ICCC) operates in the In Vitro & In Vivo Diagnostic Substances industry, within the Healthcare sector.
IMMUCELL CORP /DE/ (ICCC) reported annual revenue of $26 million in its most recent fiscal year, based on SEC EDGAR filings.
IMMUCELL CORP /DE/ (ICCC) has a net profit margin of -8.1%. The company is currently unprofitable.
IMMUCELL CORP /DE/ (ICCC) generated $-108 thousand in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
IMMUCELL CORP /DE/ (ICCC) has a debt-to-equity ratio of 0.60. This indicates moderate leverage.
IMMUCELL CORP /DE/ (ICCC) reported earnings per share (EPS) of $-0.26 in its most recent fiscal year.
IMMUCELL CORP /DE/ (ICCC) has a return on equity (ROE) of -8.2%. A negative ROE may indicate losses or negative equity.
IMMUCELL CORP /DE/ (ICCC) has a 5-year average gross margin of 36.6%. This indicates decent pricing power.
The Ledger Terminal provides 16 years of financial data for IMMUCELL CORP /DE/ (ICCC), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
IMMUCELL CORP /DE/ (ICCC) has a book value per share of $3.32, based on its most recent annual SEC filing.
No recent press releases.